CAS 361440-67-7 Pite> 98.5% (HPLC) faktori

Deskripsyon kout:

(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Asid tert-Butyl Ester

CAS: 361440-67-7

Pite:> 98.5% (HPLC)

Aparans: poud blan

Entèmedyè API (CAS: 361442-04-8)

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Entèmedyè ki gen rapò ak pwovizyon chimik Ruifu
CAS 361442-04-8
CAS 945667-22-1
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Asid tert-Butyl Ester CAS 361440-67-7
2-(3-Idroksi-1-Adamantyl) -2-Oxoacetic Asid CAS 709031-28-7

Pwopriyete chimik:

Non Chimik	(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Asid tert-Butyl Ester
Sinonim	N-Boc-L-cis-4,5-Methanoprolineamid;N-Boc-cis-4,5-Methano-L-Prolinamide;tert-Butil (1S,3S,5S)-3-Carbamoyl-2-Azabicyclo[3.1.0]hexane-2-Carboxylate
Nimewo CAS	361440-67-7
Nimewo CAT	RF-PI1990
Estati Stock	Nan Stock, Pwodiksyon Echèl Jiska Tòn
Fòmil molekilè	C11H18N2O3
Pwa molekilè	226.27
Pwen bouyi	388.9±21.0℃
Dansite	1.228
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Poud blan
Pite / Metòd analiz	>98.5% (HPLC)
Pèt sou siye	<0.50%
Rezid sou ignisyon	<0.20%
Enpurte endividyèl yo	<1.00%
Enpurte total	<1.50%
Tès Creole	Enterprise Standard
Itilizasyon	Entèmedyè API (CAS: 361442-04-8)

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Asid tert-Butyl Ester (CAS: 361440-67-7) se yon entèmedyè nan API (CAS: 361442). -04-8).(CAS: 361442-04-8) se yon ipoglisemi oral (dwòg anti-dyabetik) nan klas inibitè dipeptidyl peptidase-4 (DPP-4) dwòg.Devlopman bonè se sèlman pa Bristol-Myers Squibb;an 2007 AstraZeneca ansanm ak Bristol-Myers Squibb pou ko-devlope konpoze final la ak kolabore sou maketing dwòg la.Nan mwa jen 2008, li te anonse ke Onglyza ta dwe non komèsyal anba ki pral commercialisés.API (CAS: 361442-04-8) yo itilize kòm monoterapi oswa an konbinezon ak lòt dwòg pou tretman dyabèt tip 2.Li absòbe rapidman apre administrasyon oral epi li gen yon pwofil farmakokinetik ki konpatib ak yon fwa chak jou.Li jwe wòl nan anpeche degradasyon GLP-l.GLP-I se òmòn yo pwodwi natirèlman nan trip la apre yo fin pran manje.